EZH2 Inhibition Enhances PD‐L1 Protein Stability Through USP22‐Mediated Deubiquitination in Colorectal Cancer
Authors:
Open Access
- 22 March 2024
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 11 (23) , e2308045
Abstract
The regulation of PD‐L1 is the key question, which largely determines the outcome of the immune checkpoint inhibitors (ICIs) based therapy. However, besides the transcription level, the protein stability of PD‐L1 is closely correlated with its function and has drawn increasing attention. In this study, EZH2 inhibition enhances PD‐L1 expression and protein stability, and the deubiquitinase ubiquitin‐specific peptidase 22 (USP22) is identified as a key mediator in this process. EZH2 inhibition transcriptionally upregulates USP22 expression, and upregulated USP22 further stabilizes PD‐L1. Importantly, a combination of EZH2 inhibitors with anti‐PD‐1 immune checkpoint blockade therapy improves the tumor microenvironment, enhances sensitivity to immunotherapy, and exerts synergistic anticancer effects. In addition, knocking down USP22 can potentially enhance the therapeutic efficacy of EZH2 inhibitors on colon cancer. These findings unveil the novel role of EZH2 inhibitors in tumor immune evasion by upregulating PD‐L1, and this drawback can be compensated by combining ICI immunotherapy. Therefore, these findings provide valuable insights into the EZH2‐USP22‐PD‐L1 regulatory axis, shedding light on the optimization of combining both immune checkpoint blockade and EZH2 inhibitor‐based epigenetic therapies to achieve more efficacies and accuracy in cancer treatment.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFA1104001)
- National Natural Science Foundation of China (82272745, 82072870, 81972966, 81972966)
This publication has 75 references indexed in Scilit:
- Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitorEBioMedicine, 2022
- ZRANB1 enhances stem-cell-like features and accelerates tumor progression by regulating Sox9-mediated USP22/Wnt/β-catenin pathway in colorectal cancerCellular Signalling, 2022
- The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactionsProtein Science, 2020
- hTFtarget: A Comprehensive Database for Regulations of Human Transcription Factors and Their TargetsGenomics, Proteomics & Bioinformatics, 2020
- Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaInvestigational New Drugs, 2020
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionCell Reports, 2017
- Deubiquitination and Stabilization of PD-L1 by CSN5Cancer Cell, 2016
- Hallmarks of Cancer: The Next GenerationCell, 2011
- EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin SignalingCancer Cell, 2011
- Control of Developmental Regulators by Polycomb in Human Embryonic Stem CellsCell, 2006